You are here

Virus-Like Particle Based pan-Marburgvirus Vaccine

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911QY-18-P-0269
Agency Tracking Number: C18A-002-0010
Amount: $149,998.54
Phase: Phase I
Program: STTR
Solicitation Topic Code: CBD18A-002
Solicitation Number: 2018.0
Solicitation Year: 2018
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-09-20
Award End Date (Contract End Date): 2019-03-20
Small Business Information
301 1st Street SW Suite 200
Roanoke, VA 24011
United States
DUNS: 627132913
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Dr. Ziyou Zhou
 (434) 483-4244
Business Contact
 Maggie Hudson
Phone: (434) 483-4254
Research Institution
 Florida International University
 Robert Guteirrez
11200 S.W. 8 Street, MARC 430
Miami, FL 33199-0001
United States

 (305) 348-2494
 Nonprofit College or University

Marburg virus (MARV) is a filamentous enveloped non-segmented negative sense RNA virus. This viruse is considered to be extremelydangerous with case fatality rates as high as 88-90%. Extensive efforts have gone towards effective vaccines for MARV prevention, however,none have been successfully established as licensed vaccines. Glycoprotein (GP) is the only surface protein of MARV. There are substantialantigenic differences between GP from different strains of MARV which account for a lack of cross-protective immunity between MARV species.Significant progress has been made using recombinant viral vectors. However, genome size restrictions of most vaccine vectors allow thevectors to accommodate only a single MARV GP gene. An ideal vaccine would be able to protect against all relevant subtypes, since in theevent of a MARV outbreak or biological attack, the identity of the species of MARV will not be immediately known. Luna proposes to develop avirus-like particle (VLP) for delivery of GP from multiple strains of MARV as a kind of effective vaccine for MARV prevention. Lunas MARV vaccinegains its edge over existing technologies because of its enhanced cross-reactivity, increased stability, and reduced cost for long-lasting MARV

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government